← Back to Screener
Propanc Biopharma, Inc. Common Stock (PPCB)
Price$0.12
Favorite Metrics
Price vs S&P 500 (26W)-102.29%
Price vs S&P 500 (4W)-15.39%
Market Capitalization$2.33M
All Metrics
Book Value / Share (Quarterly)$-0.20
Cash Flow / Share (Quarterly)$-41.67
Price vs S&P 500 (YTD)-83.32%
EPS (TTM)$-141.08
10-Day Avg Trading Volume12.52M
EPS Excl Extra (TTM)$-141.08
EPS (Annual)$-1070.90
Cash / Share (Quarterly)$1.01
ROA (Last FY)-2515.59%
EBITD / Share (TTM)$-0.08
Cash Flow / Share (Annual)$-97.61
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-3.16x
ROA (TTM)-2651.69%
EPS Incl Extra (Annual)$-1070.90
Current Ratio (Annual)0.01x
Quick Ratio (Quarterly)0.00x
3-Month Avg Trading Volume2.76M
52-Week Price Return-98.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.20
52-Week High$11.00
EPS Excl Extra (Annual)$-1070.90
26-Week Price Return-93.54%
Quick Ratio (Annual)0.01x
13-Week Price Return-73.65%
Current Ratio (Quarterly)0.00x
Enterprise Value$3.522
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.20
3-Month Return Std Dev145.31%
Net Income / Employee (TTM)$-2
Net Interest Coverage (Annual)-2.51x
EPS Basic Excl Extra (Annual)$-1070.90
EPS Incl Extra (TTM)$-141.08
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.52
Free OCF CAGR (5Y)-36.13%
Price vs S&P 500 (52W)-98.56%
Year-to-Date Return-79.18%
5-Day Price Return10.59%
EPS Normalized (Annual)$-1070.90
ROA (5Y Avg)-6091.66%
Month-to-Date Return5.38%
Cash Flow / Share (TTM)$-0.55
EBITD / Share (Annual)$-871.29
EPS Basic Excl Extra (TTM)$-141.08
Book Value / Share (Annual)$-0.52
Price vs S&P 500 (13W)-76.51%
Beta3.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-1743.60%
52-Week Low$0.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PPCBPropanc Biopharma, Inc. Common Stock | — | — | — | — | $0.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Propanc Biopharma is a development-stage biopharmaceutical company focused on oncology treatments for pancreatic, ovarian, and colorectal cancers. The company's lead candidate, PRP, is a composite formulation designed to prevent tumor recurrence and metastasis through a novel proenzyme-based approach. The product combines multiple anti-cancer mechanisms intended to improve treatment outcomes in difficult-to-treat solid tumors.